Abstract :

Antinuclear antibodies (ANA) and a type of antibodies that are produced against macromolecules in cell nuclei or the cytoplasm. Indirect immunofluorescence is the most widely method to detect ANA with additional solid phase assays also being available. All the patient admitted to the ICU and had their ANA levels drawn at the SMDC within the past three years (Jan 2017 to Dec 2019) were included in the study.  In patient with multiple hospitalizations, the most recent one was considered for the study. ANA levels were detected using immunofluorescence assay technique. Between Jan 2017 and Dec 2019, 600 patients had their ANA levels drawn, out of which 78 were positive and 522 were negative. Out of the ANA positive patients, 14 (17 percent) had the values to 1:40, 29 (35 percent) had values to 1:80, 14 (17 percent) had values to 1:160, 8 (9.7 percent) had values to 1: 320, 11 (13.2 percent) had values to 1:640, 4 (4.8 percent) had values to 1:1280, 2 (2.4 percent) had values greater than >1:1280. It is concluded that in patients with RA, important differences exist between those who are ANA‐positive and ANA‐negative in terms of time to fulfillment of RA criteria and time to DMARD initiation as well as choice of initial pharmacotherapy.

---

Keywords :

Antinuclear antibodies, SMDC.

---

References :

1. Paknikar, S. S., Crowson, C. S., Davis, J. M., & Thanarajasingam, U. (2021). Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis. ACR open rheumatology, 3(6), 422–426. https://doi.org/10.1002/acr2.11271
2. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken)2012;64:625–39.
3. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux‐Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs. Ann Rheum Dis2010;69:964–75
4. Ishikawa Y, Hashimoto M, Ito H, Tanaka M, Yukawa N, Fujii T, et al. Anti‐nuclear antibody development is associated with poor treatment response to biological disease‐modifying anti‐rheumatic drugs in patients with rheumatoid arthritis. Semin Arthritis Rheum2019;49:204–10
5. Jani M, Dixon WG, Chinoy H. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. Rheumatology (Oxford)2018;57:1896–907
6. Li Q‐Z, Karp DR, Quan J, Branch VK, Zhou J, Lian Y, et al. Risk factors for ANA positivity in healthy persons. Arthritis Res Ther2011;13:R38.
7. Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin DC, et al. Increasing prevalence of antinuclear antibodies in the United States. Arthritis Rheumatol2020;72:1026–35
8. Solow EB, Vongpatanasin W, Skaug B, Karp DR, Ayers C, de Lemos JA. Antinuclear antibodies are associated with all‐cause mortality and cardiovascular outcomes in the general population. J Am Coll Cardiol2015;65:2669–70.
9. Garcia‐de LaTorre I, Garcia‐Valladares I. Antinuclear antibody (ANA) testing in patients treated with biological DMARDs: is it useful? [Review Article]. Curr Rheumatol Rep2015;17:23.
10. De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti‐tumour necrosis factor α therapy: a French national survey. Arthritis Res Ther2005;7:R545–51.
11. Takase K, Horton SC, Ganesha A, Das S, McHugh A, Emery P, et al. What is the utility of routine ANA testing in predicting development of biological DMARD‐induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single‐centre cohort. Ann Rheum Dis2014;73:1695–9.
12. Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ III. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc2012;87:1202–13.